Document Type
Journal Article
Publication Date
1-1-2020
Journal
Front Oncol
Volume
10
DOI
10.3389/fonc.2020.01226
Keywords
EZH2; H3K27me3; MCL; PRC2; cdkn2b.
Abstract
The polycomb repressive complex 2 (PRC2) maintains the transcriptional repression of target genes through its catalytic component enhancer of zeste homolog 2 (EZH2). Through modulating critical gene expression, EZH2 also plays a role in cancer development and progression by promoting cancer cell survival and invasion. Mutations in EZH2 are prevalent in certain B-cell lymphoma subtypes such as diffuse large cell lymphoma and follicular lymphoma; while no EZH2 mutation has been reported in the mantle cell lymphoma (MCL). Here we demonstrate that the PRC2 components EZH2, EED and SUZ12 are upregulated in the MCL cells as compared to normal B-cells. Moreover, stably transfected cells with wild-type EZH2 or-EED showed increased cell growth and H3K27-trimehtylation. However, unlike wild-type EZH2, ectopic expression of a deletion construct of EZH2 (EZH2
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
APA Citation
Demosthenous, C., Gupta, S., Sun, J., Wang, Y., Troska, T., & Gupta, M. (2020). Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of. Front Oncol, 10 (). http://dx.doi.org/10.3389/fonc.2020.01226
Peer Reviewed
1
Open Access
1
Comments
Copyright © 2020 Demosthenous, Gupta, Sun, Wang, Troska and Gupta.